ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?

ABBV fell after cutting its 2026 EPS outlook, attributing the change to the Apogee deal, even though it delivered strong Q2 results. The company also raised revenue guidance and highlighted growth momentum from key medicines. Net takeaway: execution looks solid near-term, but investors are de-risking the longer-term EPS path tied to the acquisition.

Analysis

ABBV fell after cutting its 2026 EPS outlook, attributing the change to the Apogee deal, even though it delivered strong Q2 results. The company also raised revenue guidance and highlighted growth momentum from key medicines. Net takeaway: execution looks solid near-term, but investors are de-risking the longer-term EPS path tied to the acquisition.